Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04467671 · ClinicalTrials.gov registry record · Phase 2
Two-Year Study of the Safety and Efficacy of the Second-Generation Tissue Engineered Vascular Grafts
A Phase 2 study of Cardiovascular Diseases and Single-ventricle, sponsored by Nationwide Children's Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT04467671 is a Phase 2 study of Cardiovascular Diseases and Single-ventricle that is actively recruiting participants, run by Nationwide Children's Hospital. The registered enrollment target is 24 participants, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04467671, a Phase 2 study of Cardiovascular Diseases and Single-ventricle, is actively recruiting participants, sponsored by Nationwide Children's Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
A single arm clinical trial evaluating the safety and efficacy of the second generation TEVG as vascular conduits for extracardiac total cavopulmonary connection.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Tissue Engineered Vascular Grafts
Study Locations (1)
Ohio
- Nationwide Children's Hospital - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2020-07-15 |
| Est. Completion | 2027-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04467671
The ClinicalTrials.gov registry entry for NCT04467671 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower). The listed sponsor is Nationwide Children's Hospital, which has 188 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 1 intervention - of which Tissue Engineered Vascular Grafts is the first listed.
NCT04467671 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT04467671 about?
NCT04467671 is a clinical study titled "Two-Year Study of the Safety and Efficacy of the Second-Generation Tissue Engineered Vascular Grafts". A single arm clinical trial evaluating the safety and efficacy of the second generation TEVG as vascular conduits for extracardiac total cavopulmonary connection.
What is the current status of trial NCT04467671?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2020-07-15. Estimated completion is 2027-08.
What conditions does trial NCT04467671 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, Single-ventricle, Heart Defects, Congenital, Cardiovascular Abnormalities, HLH - Hypoplastic Left Heart Syndrome.
What interventions are being tested in trial NCT04467671?
The interventions under investigation include: Tissue Engineered Vascular Grafts (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04467671?
This trial is sponsored by Nationwide Children's Hospital, which has 188 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04467671 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals
RECRUITING · Phase 2
-
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
RECRUITING · Phase 2
-
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
RECRUITING · Phase 2
-
Omega-3D: Omega-3 for Diet-Driven Health Disparities
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Virtual Care Strategies to Improve Participation in Cardiac Rehabilitation Among Veterans
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.